Department of Family and Community Medicine, Baylor College of Medicine, Houston, TX, USA.
Harris Health System, Houston, TX, USA.
J Antimicrob Chemother. 2024 Mar 1;79(3):559-563. doi: 10.1093/jac/dkae004.
Risk factors for ciprofloxacin or MDR in primary care urine specimens are not well defined.
We created a primary care-specific antibiogram for Escherichia coli isolates from cases with complicated and uncomplicated urinary tract infection (UTI) and evaluated risk factors for ciprofloxacin, trimethoprim/sulfamethoxazole and MDR among Enterobacterales.
We conducted a cross-sectional study to determine resistance and risk factors by collecting urine cultures from all patients (≥18 years) presenting with provider-suspected UTI at two primary care, safety-net clinics in Houston, TX, USA between November 2018 and March 2020.
Among 1262 cultures, 308 cultures grew 339 uropathogens. Patients with Enterobacterales (n = 199) were mostly female (93.5%) with a mean age of 48.5 years. E. coli was the predominant uropathogen isolated (n = 187/339; 55%) and had elevated trimethoprim/sulfamethoxazole (43.6%) and ciprofloxacin (29.5%) resistance, low nitrofurantoin (1.8%) resistance, and no fosfomycin resistance. Among E. coli, 10.6% were ESBL positive and 24.9% had MDR. Birth outside the U.S.A., prior (2 year) trimethoprim/sulfamethoxazole resistance, and diabetes mellitus were associated with trimethoprim/sulfamethoxazole resistance. Prior (60 day) fluoroquinolone use, prior ciprofloxacin resistance and both diabetes mellitus and hypertension were strongly associated with ciprofloxacin resistance. Prior fluoroquinolone use and a history of resistance to any studied antibiotic were associated with MDR, while pregnancy was protective.
We found elevated resistance to UTI-relevant antimicrobials and novel factors associated with resistance; these data can be incorporated into clinical decision tools to improve organism and drug concordance.
初级保健尿液标本中氟喹诺酮类或 MDR 的危险因素尚未明确。
我们为复杂性和非复杂性尿路感染(UTI)病例中分离的大肠埃希菌创建了一个特定于初级保健的抗生素谱,并评估了肠杆菌科中氟喹诺酮类、复方磺胺甲噁唑和 MDR 的危险因素。
我们进行了一项横断面研究,通过在美国德克萨斯州休斯顿的两家初级保健、安全网诊所收集所有(≥18 岁)疑似 UTI 患者的尿液培养物来确定耐药性和危险因素,时间为 2018 年 11 月至 2020 年 3 月。
在 1262 个培养物中,308 个培养物培养出 339 种尿路病原体。肠杆菌科患者(n=199)主要为女性(93.5%),平均年龄为 48.5 岁。分离出的主要尿路病原体为大肠埃希菌(n=187/339;55%),对复方磺胺甲噁唑(43.6%)和氟喹诺酮(29.5%)耐药率较高,对呋喃妥因(1.8%)耐药率较低,无磷霉素耐药性。在大肠埃希菌中,10.6%为 ESBL 阳性,24.9%为 MDR。出生于美国境外、既往(2 年)复方磺胺甲噁唑耐药以及糖尿病与复方磺胺甲噁唑耐药相关。既往(60 天)氟喹诺酮使用、既往氟喹诺酮耐药以及糖尿病和高血压均与氟喹诺酮耐药密切相关。既往氟喹诺酮使用史和任何研究抗生素耐药史与 MDR 相关,而妊娠具有保护作用。
我们发现与 UTI 相关的抗菌药物耐药率升高,并发现了与耐药性相关的新因素;这些数据可以纳入临床决策工具,以提高病原体和药物的一致性。